• VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs

    25 days ago - By Xconomy

    Dave Johnson has known UC San Diego physician and cancer reseacher Thomas Kipps for nearly 20 years. Now Johnson, CEO of San Diego-based cancer drug developer VelosBio, has secured $137 million to accelerate the company's goal of developing targeted therapies based on an antibody program developed by Kipps that homes in on tumors with a specific genetic signature. Johnson said it was Kipps' work, which identified ROR1 as a promising cancer protein to target and developed a drug candidate that appeared to find cancer cells that expressed it without harming healthy cells, that “compelled”...
    Read more ...